vs
Side-by-side financial comparison of Amgen (AMGN) and TRINITY BIOTECH PLC (TRIB). Click either name above to swap in a different company.
Amgen is the larger business by last-quarter revenue ($9.9B vs $30.5M, roughly 323.0× TRINITY BIOTECH PLC). Amgen runs the higher net margin — 13.5% vs -33.0%, a 46.5% gap on every dollar of revenue. Amgen produced more free cash flow last quarter ($961.0M vs $-4.1M).
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Trinity Biotech PLC develops, manufactures and markets diagnostic test kits and systems for clinical laboratories and point-of-care settings. Its product portfolio covers diabetes management, infectious diseases, cardiac health, autoimmune disorders and coagulation, with core markets across North America, Europe and emerging economies.
AMGN vs TRIB — Head-to-Head
Income Statement — Q4 2025 vs Q2 2024
| Metric | | |
|---|---|---|
| Revenue | $9.9B | $30.5M |
| Net Profit | $1.3B | $-10.1M |
| Gross Margin | 69.8% | 36.8% |
| Operating Margin | 27.6% | -23.2% |
| Net Margin | 13.5% | -33.0% |
| Revenue YoY | 8.6% | — |
| Net Profit YoY | 112.6% | — |
| EPS (diluted) | $2.45 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.9B | — | ||
| Q3 25 | $9.6B | — | ||
| Q2 25 | $9.2B | — | ||
| Q1 25 | $8.1B | — | ||
| Q4 24 | $9.1B | — | ||
| Q3 24 | $8.5B | — | ||
| Q2 24 | $8.4B | $30.5M | ||
| Q1 24 | $7.4B | — |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $2.8B | — | ||
| Q2 24 | $746.0M | $-10.1M | ||
| Q1 24 | $-113.0M | — |
| Q4 25 | 69.8% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.4% | 36.8% | ||
| Q1 24 | 57.0% | — |
| Q4 25 | 27.6% | — | ||
| Q3 25 | 26.4% | — | ||
| Q2 25 | 28.9% | — | ||
| Q1 25 | 14.5% | — | ||
| Q4 24 | 25.4% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 22.8% | -23.2% | ||
| Q1 24 | 13.3% | — |
| Q4 25 | 13.5% | — | ||
| Q3 25 | 33.7% | — | ||
| Q2 25 | 15.6% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 33.3% | — | ||
| Q2 24 | 8.9% | -33.0% | ||
| Q1 24 | -1.5% | — |
| Q4 25 | $2.45 | — | ||
| Q3 25 | $5.93 | — | ||
| Q2 25 | $2.65 | — | ||
| Q1 25 | $3.20 | — | ||
| Q4 24 | $1.17 | — | ||
| Q3 24 | $5.22 | — | ||
| Q2 24 | $1.38 | — | ||
| Q1 24 | $-0.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.1B | $5.3M |
| Total DebtLower is stronger | $54.6B | — |
| Stockholders' EquityBook value | $8.7B | $-29.4M |
| Total Assets | $90.6B | $94.4M |
| Debt / EquityLower = less leverage | 6.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.1B | — | ||
| Q3 25 | $9.4B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $8.8B | — | ||
| Q4 24 | $12.0B | — | ||
| Q3 24 | $9.0B | — | ||
| Q2 24 | $9.3B | $5.3M | ||
| Q1 24 | $9.7B | — |
| Q4 25 | $54.6B | — | ||
| Q3 25 | $54.6B | — | ||
| Q2 25 | $56.2B | — | ||
| Q1 25 | $57.4B | — | ||
| Q4 24 | $60.1B | — | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
| Q4 25 | $8.7B | — | ||
| Q3 25 | $9.6B | — | ||
| Q2 25 | $7.4B | — | ||
| Q1 25 | $6.2B | — | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $7.5B | — | ||
| Q2 24 | $5.9B | $-29.4M | ||
| Q1 24 | $5.0B | — |
| Q4 25 | $90.6B | — | ||
| Q3 25 | $90.1B | — | ||
| Q2 25 | $87.9B | — | ||
| Q1 25 | $89.4B | — | ||
| Q4 24 | $91.8B | — | ||
| Q3 24 | $90.9B | — | ||
| Q2 24 | $90.9B | $94.4M | ||
| Q1 24 | $93.0B | — |
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.6B | $-3.9M |
| Free Cash FlowOCF − Capex | $961.0M | $-4.1M |
| FCF MarginFCF / Revenue | 9.7% | -13.3% |
| Capex IntensityCapex / Revenue | 6.5% | 0.5% |
| Cash ConversionOCF / Net Profit | 1.20× | — |
| TTM Free Cash FlowTrailing 4 quarters | $8.1B | $-4.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | — | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $3.6B | — | ||
| Q2 24 | $2.5B | $-3.9M | ||
| Q1 24 | $689.0M | — |
| Q4 25 | $961.0M | — | ||
| Q3 25 | $4.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $980.0M | — | ||
| Q4 24 | $4.4B | — | ||
| Q3 24 | $3.3B | — | ||
| Q2 24 | $2.2B | $-4.1M | ||
| Q1 24 | $459.0M | — |
| Q4 25 | 9.7% | — | ||
| Q3 25 | 44.4% | — | ||
| Q2 25 | 20.8% | — | ||
| Q1 25 | 12.0% | — | ||
| Q4 24 | 48.4% | — | ||
| Q3 24 | 39.0% | — | ||
| Q2 24 | 26.5% | -13.3% | ||
| Q1 24 | 6.2% | — |
| Q4 25 | 6.5% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 2.8% | 0.5% | ||
| Q1 24 | 3.1% | — |
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.59× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 7.61× | — | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | 3.30× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
TRIB
Segment breakdown not available.
